Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AT-527 Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320
View directory record Official record
Conditions
Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

NCT05629962
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
Interventions
Bemnifosbuvir (BEM), Placebo
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Kingman, Arizona • Prescott, Arizona • Surprise, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

NCT05004415
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
AT-527 (R07496998)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 2, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

NCT04396106
View directory record Official record
Conditions
COVID-19
Interventions
AT-527, Placebo
Drug · Other
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Davis, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693
View directory record Official record
Conditions
Healthy Volunteer, Hepatic Impairment
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Study of Bemnifosbuvir in Healthy Japanese Subjects

NCT05905497
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

NCT05904470
View directory record Official record
Conditions
Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV
Interventions
Bemnifosbuvir, Ruzasvir
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

NCT07007806
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 2, 2026, 8:10 AM EDT